Objectives Infants (age 12 months and younger) are the most difficult population of cancer patients to treat. Historically, radiation would be excluded from treatment options and this view remains prevalent worldwide. New radiation technology may shift this perspective. The purpose of this study is ...
In this context indoleamine 2,3-dioxygenase 1 (IDO1) is one of the most studied target of cancer immunotherapies by virtue of its effects on immune suppression in the TME[6]. IDO1, a monomeric heme-containing enzyme, is one of the three enzymes that catalyze the first and rate-limiting ...
T-VEC is currently being evaluated as a potential treatment in melanoma and other advanced cancers [19, 20]. In a pre-clinical study in breast cancer bearing mice, the combination of an anti-PD1 antibody and a multi-peptide vaccine prolonged the vaccine-induced progression-free survival (PFS)...
Progression-free survival(PFS) is a term often used in clinical trials evaluating new drugs and treatments. It refers to the amount of time between when a treatment for cancer begins, and when cancer progresses or death occurs.1 Disease-Free Survival Disease-free survival is a measure of the ...
3. Enhertu is used for the treatment of adults with hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, that cannot be removed by surgery or has spread in the body (metastatic) and ...
Join top leaders in the lung cancer field as they share their insights on COVID-19 and how the pandemic is poised to have a significant impact on lung cancer treatment and the health care system on Thursday, May 14, 2020 at 8 PM EST....
In this context indoleamine 2,3-dioxygenase 1 (IDO1) is one of the most studied target of cancer immunotherapies by virtue of its effects on immune suppression in the TME[6]. IDO1, a monomeric heme-containing enzyme, is one of the three enzymes that catalyze the first and rate-limiting ...
in the prevention of autoimmune reactions [1]. However, the same mechanisms can be exploited by cancer cells to elude immune system attack [2]. Indeed, it is well known that the upregulation of these molecules in immune cells infiltrating the tumor microenvironment (TME) or on cancer cells ...
SBRT is not an established or accepted alternative to BCT. However, in certain patients, BCT is precluded by coexisting medical conditions, unfavourable anatomy (too close to OARs or unfavourable tumor size in terms of achieving adequate dosimetric coverage; further, some patients occasionally refuse ...
This is the first clinical trial of novel coronavirus innovative drug independently developed in China published by NEJM. The clinical results show that for adult patients with mild to moderate Covid-19 with high risk factors, VV116 made in China is not inferior to Paxlovid in terms of duratio...